Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZI(TM)) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locall...

Descripción completa

Detalles Bibliográficos
Autores principales: Witlox, Willem J. A., van Asselt, Antoinette D. I., Wolff, Robert, Armstrong, Nigel, Worthy, Gill, Chalker, Annette, Buksnys, Titas, Stirk, Lisa, Kleijnen, Jos, Joore, Manuela A., Grimm, Sabine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080309/
https://www.ncbi.nlm.nih.gov/pubmed/31814080
http://dx.doi.org/10.1007/s40273-019-00870-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080309/
https://www.ncbi.nlm.nih.gov/pubmed/31814080
http://dx.doi.org/10.1007/s40273-019-00870-w

Ejemplares similares